PITTSBURGH – November 3, 2020 – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced that Larry Brown, Sc.D., the company’s Executive Vice President and Chief Scientific Officer, will present a talk entitled, “Neuroprotection by Intranasal ST266, an Amnion Multipotent Progenitor Cell-Derived Secretome” at the virtual 10th Annual Traumatic Brain Injury Conference at 1:35 pm EST on November 03, 2020.
Dr. Brown will discuss the development of Noveome’s neuroprotective program which is evaluating intranasal “nose-to-brain” delivery of its novel platform biologic, ST266, to treat traumatic brain injury and optic nerve/retinal diseases and injuries. ST266 is a cGMP-produced secretome, secreted by proprietary Amnion-derived Multipotent Progenitor (AMP) cells. AMP cells are produced by culturing a select population of amnion-derived epithelial cells under proprietary conditions. This cell secretome is anti-inflammatory, neuroprotective, and anti-apoptotic. Noveome has demonstrated successful intranasal delivery of this secretome to the brain via the olfactory nerves. With evidence of neuroprotection in animal models, the program has now advanced into Phase 1 human trials using a targeted intranasal device to deliver ST266 directly to the brain and eye. This trial is being conducted at The University of Pennsylvania.
ST266 is a cell-free platform biologic containing hundreds of proteins and other factors in physiologic levels that are involved in cellular healing, protection of the brain and nerves, and modulation of inflammation. ST266 is the first potential therapeutic focused on treating the underlying nerve degeneration that occurs in glaucoma, optic nerve and retinal diseases and injuries using an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the optic nerve and eye, by-passing the blood-brain barrier. Noveome has multiple successful preclinical studies available for reference. Topline data from Noveome’s Phase 1 open-label clinical trial in Glaucoma Suspect patients are expected in the fourth quarter of 2020.
About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. In addition to the Phase 1 trial described above, the company recently announced the results of a Phase 2 open-label clinical trial evaluating ST266 as a treatment for Persistent Corneal Epithelial Defects (PEDs). ST266 was found to be both safe and beneficial in treating PEDs. Additional clinical trials are being planned, including a Phase 2b PED trial and a Phase 2 wet Age-related Macular Degeneration trial. Noveome recently initiated a clinical program to evaluate the ability of ST266 to treat the severe inflammatory response called “cytokine storm” that occurs in some COVID-19 patients. This Phase 1 intravenous trial on COVID-19 patients is expected to begin in the first quarter of 2021. To date, Noveome has received over $160 million in research and infrastructure funding. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.
Stern Investor Relations, Inc.